Recruiting

Testing a new hormone therapy combined with existing breast cancer drugs

Plain-English translation of NCT07002177 on ClinicalTrials.gov ↗ · Source last updated January 2026 · Translation generated August 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing , a new medication designed to block estrogen receptors in hormone-sensitive breast cancer cells. Researchers are combining this medication with one of several existing breast cancer drugs to see if the combination works better and is safe for people whose cancer has spread or cannot be surgically removed. The goal is to find which combinations are most effective for treating this type of advanced breast cancer.

Many people with hormone-receptor-positive breast cancer eventually stop responding to standard hormone therapies. This medication is being tested to offer patients a new treatment option when existing options no longer work or are no longer tolerated.

Do you qualify?

You likely qualify if…

you have been diagnosed with hormone-receptor-positive, HER2-negative breast cancer that is advanced or cannot be surgically removed
your cancer has gotten worse despite previous hormone therapy or chemotherapy, or you could not tolerate those treatments
you are willing to provide blood samples for genetic testing of your cancer
you are postmenopausal, have had both ovaries removed, or are willing to take hormone-blocking injections during the study
your organs and bone marrow are functioning well enough for the trial, as confirmed by lab tests

You likely don't qualify if…

you have cancer that has spread to the brain's protective lining or is causing spinal cord problems
you have serious digestive problems that would prevent your body from absorbing oral medications
you have unstable cancer spread to your lungs, fluid buildup around your organs, or active lung inflammation
you have type 1 diabetes or type 2 diabetes that is not well controlled (for the everolimus combination arm only)
you have a history of lung disease or scarring of the lungs from previous medications

What participation looks like

You would take the new medication by mouth, combined with one of several existing breast cancer drugs that your doctor selects based on your previous treatments and cancer characteristics. Depending on your situation, you may also receive hormone-blocking injections. You will attend regular clinic visits for blood work, imaging scans, and check-ins with your medical team to monitor how well the treatment is working and watch for side effects. The study will continue as long as the treatment is helping your cancer and you are tolerating it well.

AI-generated summary from trial data · Aug 14, 2026 · Not medical advice

Trial locations(1 site)

China

Fudan University Shanghai Cancer Center, Shanghai, Shanghai